KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Free Cash Flow (2016 - 2025)

Pfizer (PFE) has disclosed Free Cash Flow for 17 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 22.42% to $4.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 billion, a 7.73% decrease, with the full-year FY2025 number at $9.1 billion, down 7.73% from a year prior.
  • Free Cash Flow was $4.5 billion for Q4 2025 at Pfizer, up from $4.0 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $25.0 billion in Q4 2021 to a low of -$2.4 billion in Q2 2024.
  • A 5-year average of $5.3 billion and a median of $4.1 billion in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 768.6% in 2021, then plummeted 128.6% in 2023.
  • Pfizer's Free Cash Flow stood at $25.0 billion in 2021, then fell by 26.07% to $18.5 billion in 2022, then crashed by 77.26% to $4.2 billion in 2023, then skyrocketed by 38.32% to $5.8 billion in 2024, then fell by 22.42% to $4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Free Cash Flow are $4.5 billion (Q4 2025), $4.0 billion (Q3 2025), and -$1.2 billion (Q2 2025).